# US 11,440,911 B2 · Salts and crystals

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,440,911 B2
- Document ID: US11440911B2
- Status: Granted
- Kind: B2
- Application number: 16/649,515
- Filed: 2018-09-26
- Published: 2020-08-06
- Granted: 2022-09-13
- Earliest claimed: 2017-09-26
- Assignees: Intra-Cellular Therapies, Inc.
- Applicants: Intra-Cellular Therapies, Inc.
- Inventors: Lawrence P. Wennogle; Peng Li; Edwin Aret
- Web page: https://patentgrep.com/patent/US11440911B2

## CPC

- C07D 471/16: Peri-condensed systems
- A61P 25/00: Drugs for disorders of the nervous system
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The disclosure provides new, stable, pharmaceutically acceptable hydrochloride salt forms of 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, together with methods of making and using them, and pharmaceutical compositions comprising them.

## Claims

### Claim 1

A hydrochloride salt of 1-(4-fluoro-phenyl)-4-((6bR, 10aS)-3-methyl-2,3,6b,9, 10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, wherein the salt is in crystalline form and wherein the crystalline form is selected from the group consisting of: polymorph 1 corresponding to FIG. 1, polymorph 2 corresponding to FIG. 2, or polymorph 3 corresponding to FIG. 3.

### Claim 2 (depends on 1)

The salt according to claim 1 which is a salt crystal, characterized as polymorph 1 and having an X-ray diffraction pattern substantially corresponding to FIG. 1.

### Claim 3 (depends on 1)

The salt according to claim 1 which is a salt crystal, characterized as polymorph 2 and having an X-ray diffraction pattern substantially corresponding to FIG. 2.

### Claim 4 (depends on 1)

The salt according to claim 1 which is a salt crystal, characterized as polymorph 3 and having an X-ray diffraction pattern substantially corresponding to FIG. 3.

### Claim 5 (depends on 1)

A pharmaceutical composition comprising a salt according to claim 1, in combination or association with a pharmaceutically acceptable diluent or carrier.